
AF2BIND predicts ligand-binding residues from a protein structure using AlphaFold2 pair representations and a 20-residue bait sequence.

Rank a compound library against one protein target with SPRINT protein and ligand co-embeddings and native cosine similarity.

Predict ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties from SMILES strings using machine learning models trained on Therapeutics Data Commons datasets.

Predict 22 ADMET properties from SMILES strings with the native Admetica Chemprop models from Datagrok.

Identify toxic, reactive, and pharmacokinetically problematic molecular fragments using structural alert patterns

Predict toxicity and synthetic accessibility of small molecules using machine learning. eToxPred combines toxicity risk assessment with synthetic accessibility scoring to help prioritize drug candidates.

Screen for lead-like compounds using stricter molecular descriptor criteria than Lipinski or Veber rules for early-stage drug discovery

Lipinski's Rule of Five predicts whether compounds will be orally bioavailable by evaluating molecular weight, LogP, hydrogen bond donors, and acceptors.

Screen compounds for Pan-Assay Interference patterns that cause false positives in biological assays

Quantitative estimate for protein-protein interaction inhibitor potential. Evaluates drug-likeness for compounds targeting PPIs.

AF2BIND predicts ligand-binding residues from a protein structure using AlphaFold2 pair representations and a 20-residue bait sequence.

Rank a compound library against one protein target with SPRINT protein and ligand co-embeddings and native cosine similarity.

Predict ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties from SMILES strings using machine learning models trained on Therapeutics Data Commons datasets.

Predict 22 ADMET properties from SMILES strings with the native Admetica Chemprop models from Datagrok.

Identify toxic, reactive, and pharmacokinetically problematic molecular fragments using structural alert patterns

Predict toxicity and synthetic accessibility of small molecules using machine learning. eToxPred combines toxicity risk assessment with synthetic accessibility scoring to help prioritize drug candidates.

Screen for lead-like compounds using stricter molecular descriptor criteria than Lipinski or Veber rules for early-stage drug discovery

Lipinski's Rule of Five predicts whether compounds will be orally bioavailable by evaluating molecular weight, LogP, hydrogen bond donors, and acceptors.

Screen compounds for Pan-Assay Interference patterns that cause false positives in biological assays

Quantitative estimate for protein-protein interaction inhibitor potential. Evaluates drug-likeness for compounds targeting PPIs.
Configure inputs to begin
Set options on the left, then click “Submit job” — or start from an example.
MYC IRES screening
SMRTnet predicts whether a small molecule is likely to interact with an RNA target from RNA sequence, RNA secondary structure, and a molecular SMILES string.
The method is useful when the RNA target has no reliable 3D structure. Many disease-associated RNAs fall into that category: internal ribosome entry sites, untranslated regions, onco-miRNAs, viral RNA elements, and repeat expansion transcripts can have experimentally supported secondary structure while lacking a stable tertiary model suitable for docking.
SMRTnet was developed by Fei and colleagues for small molecule-RNA interaction prediction without RNA tertiary structures. The model combines RNA and chemical language models with CNN, graph attention, and multimodal fusion layers, then reports an ensemble binding probability for each RNA-compound pair.
SMRTnet can be run on ProteinIQ by entering RNA targets as tab-separated name, sequence, and dot-bracket structure rows, then entering small molecules as tab-separated name and SMILES rows. The output is a ranked table of RNA-compound pairs with binding probability scores and binary interaction calls.
| Input | Accepted format | Requirements |
|---|---|---|
RNA Target(s) | Text or .txt/.tsv file with three tab-separated columns: name, sequence, structure | RNA sequence and dot-bracket structure must have the same length. Minimum length is 31 nucleotides. Sequences may use only A, C, G, U, or T; SMRTnet converts T to U. Dot-bracket notation may use only (, ), and .. |
Small Molecule(s) | Text or .txt/.tsv/.smi/.smiles file with two tab-separated columns: name, SMILES | SMILES must parse with RDKit. Invalid molecules are rejected rather than silently removed. |
RNA input should normally use RNA alphabet conventions, with U rather than T. RNA names cannot contain spaces, other whitespace, or > because SMRTnet converts the table to FASTA before slicing it. Names are carried through to the output table, so short identifiers such as MYC_IRES, pre_miR_21, or SARS2_SL5 make results easier to review.
MYC_IRES GUGGGGGCUUCGCCUCUGGCCCAGCCCUCAC (((((((((..(((...)))..)))))))))
TAU_UTR GCUAGCUAGCUAGCUAGCUAGCUAGCUAGCU ...(((((.......)))))............3902-71-4 CC1=CC(=O)OC2=C1C=C3C=C(OC3=C2C)C
caffeine CN1C=NC2=C1C(=O)N(C(=O)N2C)C
aspirin CC(=O)OC1=CC=CC=C1C(=O)OSMRTnet slices every RNA longer than 31 nucleotides into overlapping 31-nt windows with a step size of one. A run may contain at most 240,000 effective RNA-window/molecule pairs, calculated as the total number of 31-nt windows across all submitted RNA targets multiplied by the number of molecules. For example, one 90-nt RNA produces 60 windows and can be submitted with up to 4,000 molecules in one run. Multiple RNA targets share the same limit; two 90-nt RNAs produce 120 windows and can be submitted with up to 2,000 molecules.
SMRTnet returns one representative row per original RNA-compound pair, sorted by predicted binding probability. For targets longer than 31 nucleotides, SMRTnet evaluates overlapping windows and selects a window using its published aggregation logic. The selected window is included so the score remains traceable to the exact model input.
| Column | Meaning |
|---|---|
Rank | Position after sorting by binding probability. 1 is the highest-scoring pair in the job. |
Molecule | Molecule name from the small molecule input. |
RNA Target | RNA target name from the RNA input. |
Source Window ID | Native SMRTnet window identifier, formed from the RNA name and zero-based window offset. |
Selected Window Start (1-based) | Position of the selected 31-nt window in the submitted RNA. |
Selected 31-nt Window | Exact normalized RNA sequence scored for the returned row. |
Selected Window Structure | Matching 31-character dot-bracket structure scored for the returned row. |
Binding Probability | Ensemble score from 0 to 1, rounded to three decimals by SMRTnet. Higher values indicate stronger model support for interaction. |
Interaction | Yes when probability is greater than 0.5; otherwise No, matching SMRTnet's published implementation. |
The output table is downloadable and copyable for follow-up triage. The ProteinIQ tool focuses on binding prediction and ranked screening results; it does not support SMRTnet's separate attention-based binding site interpretation workflow.
The binding probability is a model score, not a dissociation constant. A score of 0.82 means the ensemble strongly classifies the pair as an interaction relative to the training distribution. It does not mean 82 percent occupancy, 82 percent experimental success, or a specific value.
| Binding probability | Practical interpretation |
|---|---|
0.8 to 1.0 | Strong model support. These pairs are reasonable first candidates for MST, SPR, SHAPE-MaP perturbation, or reporter assays, especially when the RNA structure is experimentally supported. |
0.5 to 0.8 | Positive classification with moderate confidence. Useful for ranking analogs, expanding a hit list, or checking whether related molecules score consistently. |
0.3 to 0.5 | Below the default interaction threshold but not necessarily irrelevant. Consider these only when chemistry, target biology, or external evidence already supports the pair. |
0 to 0.3 | Low model support. These pairs are usually lower priority unless the input structure is uncertain or the molecule class is outside the model's training space. |
Score differences matter most near the top of a screen. For example, a set of natural products scoring 0.91, 0.88, and 0.86 against the same RNA should generally be treated as a top tier rather than as three precisely separated affinities. Conversely, a compound scoring 0.62 against one RNA and 0.18 against closely related decoy RNAs is more interesting than the same 0.62 score without selectivity context.
Secondary structure quality strongly affects interpretation. A structure supported by SHAPE-MaP, DMS probing, enzymatic probing, or a conserved motif model carries more weight than a single minimum-free-energy fold. For secondary structure prediction before screening, ViennaRNA can help generate dot-bracket hypotheses, but computational folds should be treated as hypotheses rather than confirmed binding-ready structures.
SMRTnet is an open-source deep learning method from the Zhang lab. ProteinIQ runs the published SMRTnet inference workflow rather than reimplementing the model.
The model uses four main representations:
An attention-based multimodal fusion module combines RNA and molecule features before classification. For inference, SMRTnet uses five models from 5-fold cross-validation and aggregates their predictions with an ensemble strategy. ProteinIQ preserves SMRTnet's inference batch size of one, reports the resulting probability, and applies its greater-than-0.5 interaction rule.
The original study evaluated SMRTnet on small molecule-RNA interaction benchmarks including R-BIND, R-SIM, SMMRNA, NALDB, and a NewPub set. The authors also tested predictions experimentally across 10 disease-associated RNA targets, including mRNAs of hard-to-drug proteins, onco-miRNAs, viral RNAs, and RNA repeat expansions. Forty hits were confirmed by microscale thermophoresis with nanomolar-to-micromolar dissociation constants, and one MYC IRES-associated compound showed downstream cellular effects in cancer cell lines.
SMRTnet is best for ligand-first or target-first screening against RNA when the available structural evidence is secondary structure. It is not a replacement for RNA-ligand docking when a high-quality 3D RNA structure and binding site are available.
| Method | Best fit | Main input requirement | Main caveat |
|---|---|---|---|
| SMRTnet | Ranking small molecules against RNA targets without tertiary structures | RNA sequence, dot-bracket secondary structure, SMILES | Returns interaction probability, not binding pose or affinity. |
| RNA-ligand docking | Pose generation and binding-site hypotheses for structured RNA pockets | 3D RNA structure and prepared ligand | Sensitive to RNA conformational flexibility and receptor preparation. |
| Experimental probing plus screening | High-confidence target validation and mechanism studies | Wet-lab structure or binding data | Slower and more expensive, but needed before biological claims. |
| Protein DTI models such as SPRINT | Protein target screening with small molecules | Protein sequence or structure-aware protein representation, SMILES | Designed for proteins, not RNA. |
A practical RNA-targeting workflow often starts with structure evidence, then screening, then validation. For example, a MYC IRES or viral stem-loop can be folded or constrained with experimental probing data, screened with SMRTnet, then followed by orthogonal assays on top-ranked molecules. If a candidate affects protein expression or viral replication, additional controls are needed to distinguish direct RNA binding from indirect cellular effects.
Interaction is positive only above 0.5. For real screening campaigns, ranking, replicate evidence, chemical tractability, and target selectivity usually matter more than a single yes/no label.